Seeking Alpha

  Nektar Therapeutics - NASDAQ

10/25/2014, 11:25 PM ET
  • JINKANG | Send Message 5 Aug 2011

    NKTR from Yahoo: Net loss for the second quarter ended June 30, 2011 was $36.4 million or $0.32 loss per share as compared to a net loss of
      NKTR vs. ETF Alternatives
      Company Description
      Nektar Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients.
      Sector: Healthcare
      Industry: Biotechnology
      Country: United States